Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:OGI NASDAQ:PDSB NASDAQ:TNYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$7.76+2.4%$8.17$56.35▼$105.00$224.92M0.9512,438 shs53,233 shsOGIOrganigram Global$1.66$1.53$0.85▼$2.00$222.53M1.49742,433 shs402,133 shsPDSBPDS Biotechnology$1.16-1.7%$1.19$0.85▼$4.29$55.49M1.15536,875 shs384,247 shsTNYATenaya Therapeutics$1.20-6.3%$0.93$0.36▼$4.01$208.61M3.074.49 million shs3.47 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+2.44%-0.26%+5.01%+14.79%-88.45%OGIOrganigram Global0.00%+0.61%+3.75%+18.57%-10.75%PDSBPDS Biotechnology-1.69%-3.33%0.00%-33.71%-62.58%TNYATenaya Therapeutics-6.25%-11.11%+39.36%+102.87%-45.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$7.76+2.4%$8.17$56.35▼$105.00$224.92M0.9512,438 shs53,233 shsOGIOrganigram Global$1.66$1.53$0.85▼$2.00$222.53M1.49742,433 shs402,133 shsPDSBPDS Biotechnology$1.16-1.7%$1.19$0.85▼$4.29$55.49M1.15536,875 shs384,247 shsTNYATenaya Therapeutics$1.20-6.3%$0.93$0.36▼$4.01$208.61M3.074.49 million shs3.47 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+2.44%-0.26%+5.01%+14.79%-88.45%OGIOrganigram Global0.00%+0.61%+3.75%+18.57%-10.75%PDSBPDS Biotechnology-1.69%-3.33%0.00%-33.71%-62.58%TNYATenaya Therapeutics-6.25%-11.11%+39.36%+102.87%-45.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/AOGIOrganigram Global 0.00N/AN/AN/APDSBPDS Biotechnology 3.00Buy$10.00762.07% UpsideTNYATenaya Therapeutics 3.00Buy$6.25420.83% UpsideCurrent Analyst Ratings BreakdownLatest PDSB, AVTE, OGI, and TNYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/27/2025TNYATenaya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/7/2025TNYATenaya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.007/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AOGIOrganigram Global$117.47M1.89N/AN/A$2.07 per share0.80PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ATNYATenaya TherapeuticsN/AN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)OGIOrganigram Global-$33.39M$0.0533.21N/AN/A2.86%-8.19%-5.79%N/APDSBPDS Biotechnology-$37.61M-$0.92N/AN/AN/AN/A-184.56%-79.00%11/13/2025 (Estimated)TNYATenaya Therapeutics-$111.13M-$0.96N/AN/AN/AN/A-93.83%-75.66%11/5/2025 (Estimated)Latest PDSB, AVTE, OGI, and TNYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025OGIOrganigram Global-$0.01-$0.03-$0.02-$0.03$68.04 million$50.49 million8/13/2025Q2 2025PDSBPDS Biotechnology-$0.24-$0.21+$0.03-$0.21N/AN/A8/6/2025Q2 2025TNYATenaya Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ATNYATenaya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78OGIOrganigram GlobalN/A2.591.42PDSBPDS Biotechnology0.812.922.92TNYATenaya TherapeuticsN/A6.006.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/AOGIOrganigram Global34.63%PDSBPDS Biotechnology26.84%TNYATenaya Therapeutics90.54%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%OGIOrganigram Global0.09%PDSBPDS Biotechnology9.20%TNYATenaya Therapeutics48.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableOGIOrganigram Global860134.05 million133.93 millionOptionablePDSBPDS Biotechnology2047.03 million42.70 millionOptionableTNYATenaya Therapeutics110162.98 million83.69 millionOptionablePDSB, AVTE, OGI, and TNYA HeadlinesRecent News About These CompaniesTenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comNuveen LLC Purchases New Shares in Tenaya Therapeutics, Inc. $TNYASeptember 9, 2025 | marketbeat.comTenaya Therapeutics' (TNYA) "Buy" Rating Reiterated at HC WainwrightSeptember 4, 2025 | marketbeat.comTenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceSeptember 2, 2025 | globenewswire.comTenaya Therapeutics Reports Interim Data from Largest Pediatric MYBPC3-Associated HCM Study Highlighting Urgent Need for Novel TherapeuticsAugust 31, 2025 | quiverquant.comQTenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025August 31, 2025 | globenewswire.comTenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from HC WainwrightAugust 29, 2025 | marketbeat.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Buy" from AnalystsAugust 28, 2025 | marketbeat.comFaraz Ali Sells 14,533 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) StockAugust 20, 2025 | marketbeat.comTenaya Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | tipranks.comTenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 8, 2025 | globenewswire.comTenaya Therapeutics reports Q2 EPS (14c), consensus (19c)August 7, 2025 | msn.comTenaya (TNYA) Q2 Loss Narrows 59%August 7, 2025 | fool.comTenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 6, 2025 | globenewswire.comTenaya Therapeutics stock rises after positive safety reviews for heart gene therapiesJuly 30, 2025 | investing.comTenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as DesignedJuly 30, 2025 | globenewswire.comTNYA - Tenaya Therapeutics Inc Dividends - MorningstarJuly 8, 2025 | morningstar.comMTNYA - Tenaya Therapeutics Inc Trailing Returns - MorningstarJuly 8, 2025 | morningstar.comMTenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo FinanceJune 27, 2025 | finance.yahoo.comTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)May 16, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Deeply Undervalued, Micron Technologies Stock Isn’t Pricing in AIBy Thomas Hughes | August 14, 2025Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNHBy Leo Miller | August 20, 2025Microchip Technologies on Track for Macro Reversal and ReboundBy Thomas Hughes | August 15, 2025Amprius Technologies’ Blowout Quarter Fuels Record-Setting GrowthBy Jeffrey Neal Johnson | August 15, 2025PDSB, AVTE, OGI, and TNYA Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$7.76 +0.19 (+2.44%) As of 09/11/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Organigram Global NASDAQ:OGI$1.66 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.64 -0.02 (-0.96%) As of 09/12/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.PDS Biotechnology NASDAQ:PDSB$1.16 -0.02 (-1.69%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.20 +0.04 (+3.45%) As of 09/12/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Tenaya Therapeutics NASDAQ:TNYA$1.20 -0.08 (-6.25%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.23 +0.03 (+2.50%) As of 09/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
